U.S. pauses Eli Lilly’s trial of a coronavirus antibody treatment over safety concerns

The ACTIV-3 monoclonal antibody trial – a phase three randomized controlled trial – has been paused due to potential safety concerns, Eli Lilly confirmed to CNBC. “Safety is of the upmost importance to Lilly. We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,” a spokeswoman told CNBC. Eli Lilly’s late-stage trial of its leading monoclonal antibody…